Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Nab-Paclitaxel With PVHA and Pembrolizumab in Metastatic Pancreatic Adenocarcinoma
NCT04045730Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pegvorhyaluronidase alfa, pembrolizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Yale University. Planned start Nov 2019; status: withdrawn.
02
Drugs
pegvorhyaluronidase alfapembrolizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04045730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045730.